Clinical Trial
Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine
Affiliations
- PMID: 1341021
Item in Clipboard
Clinical Trial
Histologic changes in fibrocystic breast disease before and after treatment with bromocriptine
Rev Paul Med.
1992 Nov-Dec.
Abstract
Twenty-five women with fibrocystic breast disease were investigated in a double-blind study using treatment with bromocriptine (5 to 7.5 mg/day for 3 months) or placebo. Estradiol and progesterone measurements did not show any changes before, during or after treatment. Serum prolactin levels were reduced during the use of bromocriptine. Histologic evaluation demonstrated a decrease of epithelial hyperplasia and arrest of the cystic dilation picture after treatment with bromocriptine.
Similar articles
-
Bromocriptine treatment of cyclical mastalgia/fibrocystic breast disease: update on the European trial.Br J Clin Pract Suppl. 1989 Nov;68:26-32; discussion 49-53. Br J Clin Pract Suppl. 1989. PMID: 2488563 Clinical Trial. No abstract available.
-
Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia.Br J Clin Pract. 1989 Sep;43(9):322-7. Br J Clin Pract. 1989. PMID: 2695151 Clinical Trial.
-
[Results of chronic treatment with bromocriptine in patients with fibrocystic mastopathy].Arch Invest Med (Mex). 1988 Jul-Sep;19(3):225-9. Arch Invest Med (Mex). 1988. PMID: 3242433 Spanish. No abstract available.
-
Fibrocystic breast disease.Am Fam Physician. 1987 Oct;36(4):119-26. Am Fam Physician. 1987. PMID: 3314435 Review.
-
Fibrocystic change and fibrocystic disease of the breast.Obstet Gynecol Clin North Am. 1987 Sep;14(3):685-702. Obstet Gynecol Clin North Am. 1987. PMID: 3323971 Review.